上海瑛派药业有限公司 Shanghai Yingpai Pharmaceutical Co. LTD
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors 2023-06-01 20:30
IMPACT 2021 R&D Day: Synthetic Lethality Provides a New Platform for Targeted Cancer Therapy 2021-12-06 16:03
IMPACT Therapeutics Announced ATR Inhibitor IMP9064 IND Clearance by FDA 2021-10-29 14:12
Impact Therapeutics Announced First-Patient-Dose of Wee1 Inhibitor IMP7068 in the U.S. 2021-03-10 21:14
1